Purpurogallin

Purpurogallin

SCHEMBL1950656

CCOCC.O=c1c(O)cccc2cc(O)c(O)c(O)c12

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.76
MAPT P10636 2/20 0.76
MEN1 O00255 2/20 0.76
ALDH1A1 P00352 2/20 0.76
KMT2A Q03164 2/20 0.76
KDM4E B2RXH2 1/20 0.76
INPPL1 O15357 1/20 0.76
NSD2 O96028 1/20 0.76
TP53 P04637 1/20 0.76
POLB P06746 1/20 0.76
CYP3A4 P08684 1/20 0.76
GAA P10253 1/20 0.76
THRB P10828 1/20 0.76
PABPC1 P11940 1/20 0.76
PKM P14618 1/20 0.76
IDO1 P14902 1/20 0.76
HPGD P15428 1/20 0.76
ALOX15 P16050 1/20 0.76
PLCG1 P19174 1/20 0.76
TNNI3 P19429 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Purpurogallin SCHEMBL33853 0.87 CDK2 (1.00) CDK2MAPTMEN1ALDH1A1KMT2A
Purpurogallin SCHEMBL29481120 0.87 CDK2 (1.00) CDK2MAPTMEN1ALDH1A1KMT2A
Purpurogallin SCHEMBL2839450 0.84 CDK2 (0.93) CDK2MAPTMEN1ALDH1A1KMT2A
Purpurogallin SCHEMBL15560816 0.83 CDK2 (0.83) CDK2MAPTMEN1ALDH1A1KMT2A
SCHEMBL17071994 0.81 MEN1 (0.59) CDK2MAPTMEN1ALDH1A1KMT2A
Purpurogallin SCHEMBL28319789 0.76 MEN1 (0.76) CDK2MAPTMEN1ALDH1A1KMT2A
SCHEMBL24107152 0.76 CDK2 (0.71) CDK2MAPTMEN1ALDH1A1KMT2A
SCHEMBL15557274 0.76 CDK2 (0.77) CDK2MAPTMEN1ALDH1A1KMT2A
SCHEMBL12610186 0.76 CDK2 (0.71) CDK2MAPTMEN1ALDH1A1KMT2A
SCHEMBL17357502 0.76 ALDH1A1 (0.71) CDK2MAPTMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023085323-A1 METHOD FOR REDUCING MEASUREMENT ERRORS DUE TO HEMOLYZED HEMOGLOBIN 東洋紡株式会社 2023-05-19 WO disclosed
US-11384381-B2 Reaction accelerating agent KIKKOMAN CORPORATION (JP) 2022-07-12 US disclosed
US-11208675-B2 Reaction accelerating agent KIKKOMAN CORPORATION (JP) 2021-12-28 US disclosed
WO-2019216408-A1 METHOD FOR SUPPRESSING REDUCTIONS IN BIOLOGICAL COMPONENT MEASUREMENT REAGENT KIT SENSITIVITY 東洋紡株式会社 (JP) 2019-11-14 WO disclosed
WO-2019216407-A1 METHOD FOR SUPPRESSING DECREASE IN SENSITIVITY OF REAGENT KIT FOR MEASURING BIOLOGICAL COMPONENT 東洋紡株式会社 (JP) 2019-11-14 WO disclosed
WO-2019216406-A1 METHOD FOR SUPPRESSING REDUCTIONS IN BIOLOGICAL COMPONENT MEASUREMENT REAGENT KIT SENSITIVITY 東洋紡株式会社 (JP) 2019-11-14 WO disclosed
WO-2019216405-A1 METHOD FOR SUPPRESSING REDUCTION IN SENSITIVITY OF BIOLOGICAL-COMPONENT-MEASURING REAGENT KIT 東洋紡株式会社 (JP) 2019-11-14 WO disclosed
US-20190316174-A1 REACTION ACCELERATING AGENT KIKKOMAN CORPORATION (JP) 2019-10-17 US disclosed
US-20190300929-A1 REACTION ACCELERATING AGENT KIKKOMAN CORPORATION (JP) 2019-10-03 US disclosed
US-20110135787-A1 DEODORIZING COMPOSITION USING PEROXIDASE UNDER NEUTRALITY LOTTE CO. LTD. 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384381-B2 Reaction accelerating agent MPO, AOX1, MAOA CDK2 341/4885MAPT 4544/4885MEN1 3767/4885
US-20190316174-A1 REACTION ACCELERATING AGENT MPO, AOX1, MAOA CDK2 341/4885MAPT 4544/4885MEN1 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.